New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
As vehicle ownership expenses climb, prospective buyers face a transformed automotive landscape. From shifting pricing models to emerging technologies, here’s how to prepare for your next purchase.
Financial guru Suze Orman's blunt critique of auto leasing has reignited the buy-vs-lease debate, revealing deep divides in consumer financial strategy as industry data shows persistent leasing popularity despite economic headwinds.
California unveils a novel $200 million electric vehicle incentive program requiring matched funding from automakers and restricted to first-time EV buyers, with specific vehicle price caps to be set.
As interest rates show signs of stabilization, we analyze the current landscape for buy-to-let mortgages, examining the best deals, key considerations for investors, and expert insights on navigating a market still shaped by recent volatility.
As Nvidia prepares to report its fiscal Q4 earnings on February 25th, investors are weighing whether to buy ahead of the event. While the AI chip leader's long-term story remains compelling, a look at its recent post-earnings stock performance reveals a pattern that favors a measured approach over trying to time the market.
Deutsche Bank has upgraded NNN REIT to 'Buy' with a $47 price target, highlighting its defensive portfolio and sustainable dividends as relative strengths in a challenging real estate investment trust environment expected to persist through 2026.
Truist Securities adjusted its price target for American Healthcare REIT (NYSE: AHR) downward slightly, while affirming a Buy rating. The move comes as the firm reassesses its outlook for the broader REIT sector heading into 2026.
A massive release of Jeffrey Epstein investigation files by the Justice Department has left survivors reeling after personal information, including names and confidential statements, was left unredacted. Lawyers allege a "historic violation" of privacy, prompting urgent calls for judicial intervention.
The Department of Justice may challenge a federal judge's order to release a five-year-old boy and his father from immigration detention, a case that has ignited debate over the administration's aggressive enforcement tactics and the conditions inside family detention centers.
InterDigital has secured a new multi-year patent license agreement with LG Electronics, extending its royalty base into consumer electronics like digital TVs and display monitors, signaling a strategic diversification of its licensing revenue.
Robinhood Markets stock tumbled sharply on Monday, dragged down by a broad selloff in cryptocurrencies. Despite the plunge, some analysts see the dip as a chance to buy into the fintech platform's long-term growth story.
CNBC's Jim Cramer endorsed Carrier Global Corp. (NYSE:CARR) on his recent show, praising CEO Dave Gitlin's leadership and strategic acquisition. He recommended investors buy the stock for the long term, citing confidence in the company's positioning within the climate solutions sector.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
The Justice Department faces questions over its release of Epstein investigation records, which included a photograph of Donald Trump with his face obscured. The disclosure, part of a three-million-page document dump, has reignited scrutiny over political sensitivities and transparency in the high-profile case.
Atlanta ranks ninth nationally as a favorable market for homebuyers, driven by increased inventory and moderating prices, according to new Realtor.com data. The trend highlights a broader shift toward buyer leverage across Sun Belt metros.
Following a federal judge's order for their release, a father recounts the two-week detention of his five-year-old son by ICE, alleging inadequate medical care and harsh conditions, as the case ignites debate over immigration enforcement practices.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
Despite navigating a major venue overhaul, the Atlanta Shoe Market reports a 7% surge in pre-registrations, with brands and buyers adapting to a reimagined show floor that may boost visibility for some exhibitors.
